Woodford Patient Capital Share Discussion Threads

[minerve] 22/3/2018 17:49

Woodford's updates now in boys and girls!

[hpcg] 22/3/2018 17:40

Wow, Woodford's shills are out in force today pumping this for all they are worth. PRTA has made it up another 1.5%, pretty good for a down day in the markets, but still below where CELG came in. Meanwhile if the market goes risk off, as Woodford keeps predicting, then speculative public and private companies are going to be worth less.

[ltcm1] 22/3/2018 15:54

What can't be disputed is it's time Woody showed his face and drained the WPCT swamp.

Wouldn't it be a larf if he announced WPCT is pumping more cash into the plastic pallet gamechanger!!!

[littleweed1] 22/3/2018 15:17

mad foetus, you persist in misunderstanding the world about you. This thread is a boggy battlefield between the trolls and the normals. It may have escaped you but you trolls are completely captured by your own ideology: all you can propagate is the negative case on WPCT. ALL of you ALWAYS predict that it will go DOWN.

The majority normals, on the other hand, accept that this share can go DOWN AND UP. I have not yet, strange to relate, seen one single normal on this thread shouting or even predicting that this share is certain to go UP. This instrument is far too complicated for that. To compound your woolly minded confusion you insist in setting up the straw man argument that anybody who disagrees with your case is a WPCT bull: I have not seen such a person yet! In fact that is, as I'm sure you realise, an argument that only thick people can make.

In sum I am saying that you trolls live in a stupidly binary universe, a Manichean construct.

So to come to your proffered bet. You have said implicitly that WPCT will hit 70p. I, on the other hand, have never said, or implied, that this will hit 90p. Do you think I'm stupid? I simply don't know. I make my real money by recognising what is plainly imminent.

I should finally explain that what irritates us normals most is the strident unsupported over-confidence that you trolls display. Look at any troll post made today.

[minerve] 22/3/2018 14:55

It's getting close to April Wooders! Are we going to get an update or what?

Tick tock!

[iq151] 22/3/2018 14:34

Two pontificating unsupported opinions from two mortally wounded trolls interrupted by a nicely humorous bit of schadenfreude.

What did I tell you?

[mad foetus] 22/3/2018 14:21

I no longer have a position here and have never been short, but the discount is now absurdly low and anyone buying in now will in my view lose 10% within 3 months, probably within a few weeks.Or another way, littleweed, I would happily wager that the share price here hits 70p before it hits 90p.

[hpcg] 22/3/2018 13:45

Will go back to where it came from. And I don't mean 100p.

[andyj] 22/3/2018 11:54

A veritable rock in a stormy sea. In Woodie we trust.

[ltcm1] 22/3/2018 11:50

Guys I am pleased WPCT is up. I think the bulls here should show more belief and confidence in WPCT rather than this childish tactic of trashing any post that dares to question any of Woodford's holdings.

The Oxford Nanopore project sounds really interesting. But can you blame me for being a bit spooked after Northwest Biotheraputics and RM2???

[minerve] 22/3/2018 11:31

Most of ADVFN shouldn't be investing in the stock market! LOL

Oh sorry, I forgot, they don't. They are just a bunch of saddo spread-betters with no to little capital.

[dr biotech] 22/3/2018 11:05

PFG is ex rights today. If you don't understand what that means, you really shouldn't be investing in the stock market.



daffyjones22 Mar '18 - 09:28 - 2323 of 2324
0 0 0
After the dead cat bounce a few weeks ago, Provident is down 25% today following the rights issue
Almost at the February lows again

[minerve] 22/3/2018 10:45

ttg100

Sorry to hear your loss. With any trusts like this try and spread your investment, not over months, but over years. When shares are going up it can deliver pressure to place your investment all at once. You have to resist this urge and nurture an attitude of not caring that you might lose out on gains. Over the years you will start to see trend and that informs your build/no build decision. It is much better to average up than down. Once you perfect this it will not protect you from losses but it better protects all your capital from larger losses that create emotional feedback.

You are now ruling out trusts which may be a shame. They are generally not for me as I start to disagree with what fund managers do/choose and they can never exactly match your personal risk/return profile.

[daffyjones] 22/3/2018 09:28

After the dead cat bounce a few weeks ago, Provident is down 25% today following the rights issue
Almost at the February lows again

[ttg100] 22/3/2018 09:24

I have just sold out again at yet another loss - no more trusts for me ever again as will stick with my own judgement
Have lost money in WPCT and Jupiter Brazil - the only one doing well is Baring Global Agriculture which has plodded along nicely as don't have the time to research

GL all who stay in

[ttg100] 22/3/2018 09:19

"Shares in the Woodford Patient Capital (WPCT +
Add to favourites
) investment trust have surged after top holding Prothena (PRTA.O) announced a tie-up with biotech giant Celgene (CELG.O) in a deal that could be worth as much as $2.2 billion (£1.6 billion).
Shares in the trust jumped 7.4% to 78.2p after Prothena, which accounts for 9.8% of the portfolio, announced it would collaborate with Celgene to develop treatments for neurodegenerative diseases.
Shares in US-listed Prothena, also the seventh largest holding in Woodford's flagship Woodford Equity Income +
Add to favourites
fund, surged 23% in aftermarket trading. Prothena is a 1.9% position in the Woodford Incoms Focus +
Add to favourites
fund.
Prothena will receive a $100 million upfront payment from Celgene and a $50 million equity investment from the biotech group, as well as the rights to royalties on the sales of any products that result.
Total payments to the company as part of the tie-up, focused on three proteins, could amount to $2.2 billion.
For each of the three drugs in development, Celgene would have to pay $80 million if it exercised US rights, $55 million for global rights, and up to $562.5 million as the drugs hit regulatory and commercial milestones.
A spokesman for Woodford Investment Management said: 'The deal makes perfect sense for Prothena and allows its research and development engine to be funded by one of the leading US biotech companies.'
Shares in Prothena have been a drag on performance of both the Woodford Patient Capital trust and Woodford Equity Income fund, after the stock came under attack from short-sellers Kerrisdale Capital.
The shares suffered a further sell-off after a delay to a trial of its flagship drug, a potential therapy for AL Amyloidosis in November last year. Even with today's surge, the shares have lost nearly half their value over the last six months.
But Woodford has stuck by the stock, saying the market's reaction to the delay was misguided and that he was 'encouraged' by progress on the drug.
Woodford has been enduring one of the most challenging periods of his fund management career, with his flagship Woodford Equity Income fund languishing at the bottom of the UK Equity Income sector over one year, hurt by heavy share price falls of top holdings like Provident Financial (PFG +
Add to favourites
) and Capita (CPI +
Add to favourites
).
His Woodford Patient Capital trust has also struggled, and even with today's jump the shares remain well below their 100p price at flotation in April 2015.
The trust also received a boost yesterday from its second largest holding, unquoted Oxford Nanopore, which represents 9.5% of the portfolio.
The handheld DNA test maker's £100 million fundraising took its valuation to £1.5 billion, up from £1.25 billion at its last financing round in 2016.
Oxford Nanopore is also a 1.4% holding in the Woodford Equity Income +
Add to favourites
fund, which has also benefited from the news through its top 10 holding in IP Group (IPO +
Add to favourites
), which owns 18.3% of Oxford Nanopore. Shares in IP Group are up 10% over the last two days.
Another Woodford stock, Softcat (SCTS +
Add to favourites
) is down 12% today, however, as the IT infrastructure company, whose shares had nearly doubled over the last 12 months, succumbed to profit-taking after half-year results. Softcat accounts for 2.2% of the Woodford Income Focus fund."

[topvest] 21/3/2018 21:12

Mind you Prothena is still a pretty rubbish blue sky company! Purplebricks also still looking weak. It's about time Woodford had a bit of luck though. Not sure its changing the long term dynamic though which is down.

[hpcg] 21/3/2018 20:23

Rise is because of PRTA but note that is still trading 10% below the price Celgene bought in. Of course that in any case would not cause a squeeze (on PRTA shorts) because those were new shares. To say the investment is loose change to Celgene is an understatement; they will have the cash back through profit, profit not revenue, by the end of the week. I'm tempted to reopen my short here tomorrow, but we'll see.

[mazarin] 21/3/2018 19:55

Prothena (PRTA) collaboration with Celgene (CELG) for details see:-

[this_is_me] 21/3/2018 19:43

Toffee those who have shorted the share eg. using spread betting with tight stop losses.

[topvest] 21/3/2018 19:41

Positive news on Prothena is the reason.